Clinical Trials
14 trialsNCT06760819 2026-05-07
panSOHO
Bayer
Phase 2 Recruiting
NCT02576431 2026-04-28
NAVIGATE
Bayer
Phase 2 Completed
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT07197554 2026-02-18
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics, Inc.
Phase 1 Recruiting
NCT06943521 2025-12-11
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
Phase 1/2 Recruiting
NCT06084689 2025-09-02
EMPIRE
Institut Bergonié
Phase 2 Withdrawn
NCT05012397 2024-10-17
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
Phase 2 Terminated
NCT04584008 2024-10-15
VISIONARY
Peking University
Phase NA Active not recruiting
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT03475953 2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2 Unknown
NCT03139487 2020-01-06
PRIORITY
Asan Medical Center
Phase 2 Unknown
NCT02900248 2019-04-02
N1
CureOne
Terminated
NCT00423254 2010-08-03
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Mannkind Corporation
Phase 1 Completed